Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 0 | 3,551 | 16,097 | 15,825 | 146,267 |
| Gross Profit | N/A | 3,551 | 16,097 | 15,825 | 146,267 |
| Operating Expenses | 126,191 | 140,096 | 124,427 | 118,528 | 98,102 |
| Operating Income | -126,191 | -136,545 | -108,330 | -102,703 | 48,165 |
| Interest Expense | 7,244 | 5,367 | 5,262 | 5,158 | 5,057 |
| Other Income | 6,439 | 3,223 | 4,602 | 4,478 | 4,568 |
| Pre-tax Income | -126,996 | -138,689 | -108,990 | -103,383 | 47,676 |
| Income Tax | N/A | -3,313 | 2,025 | 742 | N/A |
| Net Income Continuous | -126,996 | -135,376 | -111,015 | -104,125 | 47,676 |
| Minority Interests | -1,696 | -2,512 | -1,336 | -1,179 | -999 |
| Net Income | $-125,300 | $-132,864 | $-109,679 | $-102,946 | $48,675 |
| EPS Basic Total Ops | -1.02 | -1.24 | -1.03 | -0.96 | 0.46 |
| EPS Basic Continuous Ops | -1.03 | -1.26 | -1.04 | -0.97 | 0.45 |
| EPS Diluted Total Ops | -1.02 | -1.24 | -1.02 | -0.96 | 0.45 |
| EPS Diluted Continuous Ops | -1.03 | -1.26 | -1.03 | -0.97 | 0.44 |
| EPS Diluted Before Non-Recurring Items | -1.02 | -1.24 | -1.03 | -0.96 | 0.45 |
| EBITDA(a) | $-119,935 | $-133,117 | $-105,458 | $-100,375 | $50,062 |